A pragmatic approach to simplifying inhaler therapy for COPD

Brian Lipworth (Lead / Corresponding author), Sunny Jabbal

Research output: Contribution to journalComment/debate

4 Citations (Scopus)
59 Downloads (Pure)
Original languageEnglish
Pages (from-to)679-681
Number of pages3
JournalThe Lancet Respiratory Medicine
Volume5
Issue number9
Early online date7 Jul 2017
DOIs
Publication statusPublished - Sep 2017

Cite this

@article{6a184acd7ef6446f9117b434b0125425,
title = "A pragmatic approach to simplifying inhaler therapy for COPD",
author = "Brian Lipworth and Sunny Jabbal",
note = "BL reports personal fees from Cipla, Dr Reddy's Laboratories, Boehringer Ingelheim, Chiesi Farmaceutici, Meda Pharmaceuticals, and Teva Pharmaceutical Industries; reports grants from Janssen, AstraZeneca, Roche, Chiesi Farmaceutici, Meda Pharmaceuticals, and Teva Pharmaceutical Industries, and grants from Sanofi outside of the submitted work; has received support to attend educational meetings from Napp, Boehringer Ingelheim, and Teva Pharmaceutical Industries; and BL's son is an employee of Boehringer Ingelheim. SJ reports personal fees from Napp, Pfizer, Chiesi Farmaceutici, and AstraZeneca; and reports support to attend educational meetings from Napp, Teva Pharmaceutical Industries, Chiesi Farmaceutici, and AstraZeneca.",
year = "2017",
month = "9",
doi = "10.1016/S2213-2600(17)30264-3",
language = "English",
volume = "5",
pages = "679--681",
journal = "The Lancet Respiratory Medicine",
issn = "2213-2600",
publisher = "Elsevier",
number = "9",

}

A pragmatic approach to simplifying inhaler therapy for COPD. / Lipworth, Brian (Lead / Corresponding author); Jabbal, Sunny.

In: The Lancet Respiratory Medicine, Vol. 5, No. 9, 09.2017, p. 679-681.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - A pragmatic approach to simplifying inhaler therapy for COPD

AU - Lipworth, Brian

AU - Jabbal, Sunny

N1 - BL reports personal fees from Cipla, Dr Reddy's Laboratories, Boehringer Ingelheim, Chiesi Farmaceutici, Meda Pharmaceuticals, and Teva Pharmaceutical Industries; reports grants from Janssen, AstraZeneca, Roche, Chiesi Farmaceutici, Meda Pharmaceuticals, and Teva Pharmaceutical Industries, and grants from Sanofi outside of the submitted work; has received support to attend educational meetings from Napp, Boehringer Ingelheim, and Teva Pharmaceutical Industries; and BL's son is an employee of Boehringer Ingelheim. SJ reports personal fees from Napp, Pfizer, Chiesi Farmaceutici, and AstraZeneca; and reports support to attend educational meetings from Napp, Teva Pharmaceutical Industries, Chiesi Farmaceutici, and AstraZeneca.

PY - 2017/9

Y1 - 2017/9

U2 - 10.1016/S2213-2600(17)30264-3

DO - 10.1016/S2213-2600(17)30264-3

M3 - Comment/debate

VL - 5

SP - 679

EP - 681

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

SN - 2213-2600

IS - 9

ER -